The core activity of Athebio AG is the development and provision of proprietary technology for the creation of targeted therapeutics with improved efficacy and safety, particularly through the use of "plug & play" DARPin technology (Athebody). The company focuses on partnering with pharmaceutical companies to develop and market innovative medicines.
AI-generated
Offering
Products & services
Industry:Research & DevelopmentPharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Athebody® DARPin platform for targeted biotherapeutics, with modular binding domains, high specificity, solubility and stability, as well as multi-specificity and protein fusion options.
Drug-Discovery-Engine
In-vitro discovery engine for the selection of binders with controlled target quality and high library diversity for preclinical and clinical development.
Partnering for biotherapeutic development projects
Flexible partnership models, joint project teams, and access to Athebody® technology for drug developers and biotherapeutics development.
Targeted AAV development
Development of targeted adeno-associated viruses for viral gene therapy, for example for neurology and ophthalmology, for directed DNA delivery into target tissues.
Targeted LNP development
Development of targeted lipid nanoparticles for non-viral gene therapy, for directed mRNA delivery into the desired tissue, for example in oncology or infectious diseases.